Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.54%
#6 Wrapped Krown Wrapped Krown +20.00%
#7 Talus Network Talus Network +19.98%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 Magma Finance Magma Finance +14.74%
Coin of the day
DeFiChain DeFiChain
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Classifica tra le azioni #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Prezzo delle azioni
$0.94180721
Capitalizzazione di mercato
$22.26M
Variazione (1 giorno)
0.38%
Variazione (1 anno)
-14.35%
Paese
FR
Scambia Valbiotis SA (ALVAL)

Categoria

Healthcare
Rapporto P/B per Valbiotis SA (ALVAL)
Rapporto P/B al July 2026 TTM: 2.69
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Valbiotis SA, il rapporto P/B attuale (TTM) è 2.69. Alla fine del 2023, era pari a 3.18.
Storico del rapporto P/B per Valbiotis SA da 2015 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 2.69 16.05%
2024 2.32 -27.16%
2023 3.18 16.23%
2022 2.74 -37.95%
2021 4.41 -30.21%
2020 6.32 392.65%
2019 1.28 -22.00%
2018 1.64 -0.78%
2017 1.66 -98.28%
2016 96.41 6,215.43%
2015 1.53 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 6.9942 159.78%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.251 132.17%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.1715 -19.35%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.065 50.98%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3009 171.17%
NL